Stock analysis, AI verdict, fundamentals & technical signals
Rating: NEUTRAL
Price: $16.03 Analyst target: $30.23 Upside: 88.58%
Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and markets drugs to treat infectious diseases in the United States, Latin America, and Europe. The company is headquartered in Cambridge, Massachusetts.
See the full interactive analysis & chart →Informational only — not investment advice.